|
[Nintedanib in lung cancer] |
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nintedanib in lung cancer] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 538. 2017 Authors' conclusions Moderate quality evidence showed that adding nintedanib to chemotherapy with docetaxel or pemetrexed as second-line regimens would not improve overall survival or quality of life of advanced lung cancer patients. Low quality evidence reports that the use with docetaxel in patients with adenocarcinoma, and mainly in those who progressed before nine months after initiating the first line of treatment, might increase overall survival in approximately three months.
In general, guidelines do not mention it as standard of care. Most health sponsors consulted do not cover it. In the United Kingdom, the use is covered by the public healthcare system as a treatment option only if there is an agreement on its price, which should be five times lower than the price stated in Argentina. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Humans; Indoles; Lung Neoplasms Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000303 Date abstract record published 13/06/2017 |
|
|
|